Earlier this month, Janssen/Pharmacyclics announced they had submitted a New Drug Application (NDA) for Food & Drug Administration (FDA) approval

 Ibrutinib leads the race to CLL 17p deletion market

Posted by 

Purchase Access to Premium Content

Click on blue icon to purchase access to all Premium Content. Current subscription rate is $399 for 3 months access, $699 for 6 months access or $1200 for 12 months access. Subscriptions do not auto renew. Rates may change without notice and are non-refundable. Please read the Terms of Use before purchasing and if in communications our Guidance to PR Professionals.